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ABStRACt
Vascular malformations or even hemangiomas need therapeutic intervention if  they start to cause clinical symptoms or 
personal discomfort. Different therapeutic modalities, including cryotherapy, corticosteroids, laser therapy, sclerotherapy, 
surgery, and/or embolization, can be performed successfully. Sclerotherapy with monoethanolamine is a relatively simple 
and effective method to treat low flow vascular lesions. We presented a report of six cases of vascular malformations 
treated with  monoethanolamine. There were 3 male and 3 female patients, with an age range of 20 to 68 years. The 
patients were submitted to applications according to clinical response and/or tolerability.  In all cases, low-flow vascular 
lesions were recorded and submitted to infiltration with 2.5% monoethanolamine, directly into the lesions. The volume 
applied was approximately the middle of affected area. Vascular lesions were characterized as low-flow due to absence 
of arterial pulsation and flat consistence. The sclerosis with 2.5% monoethanolamine resulted in complete or partial 
involution, without severe complications.
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INtRODUCtION
Vascular anomalies comprise a widely heterogeneous group 
of  tumors and malformations. Vascular malformations 
generally present at birth, and usually persist throughout 
the lifetime. Most hemangiomas undergo a progressive 
involution during the first years of  life (1,2). Vascular 
malformations or even hemangiomas require therapeutic 
intervention if  they start to cause clinical symptoms or 
personal discomfort. Based on individual parameters (such 
as diameter, location and growth dynamics), different the-
rapeutic modalities, including cryotherapy, corticosteroids, 
laser therapy, sclerotherapy, surgery, and/or embolization, 
can be performed successfully (2). Advances in laser surgery 
as well as sclerotherapy techniques have improved our abi-
lity to treat extensive lesions and these have also improved 
patients’ quality of life (3). 
Sclerotherapy of  vascular lesions is a relatively simple, 
effective, and inexpensive method that is a valuable and 
promising treatment (4). The sclerosing therapy may cause 
the complete regression of low flow vascular lesions. Even 
in the case of partial regression of the angioma, surgery of 
the remaining lesion has less bleeding (5).  Monoethano-
lamine oleate (MO) is a sclerosing agent accepted for skin 
vascular lesions and esophageal varices (6-9). Nevertheless, 
few studies deal with MO efficacy in head and neck vascular 
malformations, and particularly for intra-oral lesions (10-
11). The purpose of this article is to present the effectiveness 
of  MO sclerosing in six patients with low flow vascular 
lesions of the oral mucosa. 
CLINICAL CASES
Table 1 shows the main demographic, clinical and the-
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table 1. Clinical data, features, resolution, side effects of 6 vascular low flow lesions.
Fig. 1. Case five. Clinical features of a painless lobular reddish nodule classified as vascular “low flow” malformation (A). Clinical features 
after surgical ablation of residual lesion after three applications of MO (B). This patient also received dental treatment involving dental ex-
tractions.
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rapeutic findings, as well as the side effects and patient´s 
complaints in this series. Six patients were randomly selec-
ted for this analysis. All of them were referred to the Oral 
Diagnosis Clinic, Unimontes, complaining of oral vascular 
lesions positive to diascopy. There were 3 male and 3 female 
patients, with an age range of 20 to 68 years. All were in 
good systemic health. In all cases, low-flow vascular lesions 
were recorded and submitted to infiltration with 2.5% MO, 
diluted in distillated water, directly into the lesions. The 
volume applied was approximately the middle of affected 
area. Vascular lesions were characterized as low-flow due 
to absence of arterial pulsation and flat consistence. Even 
after needle puncture, no hemorrhage was noted. The pa-
tients were submitted to applications according to clinical 
response and/or tolerability. All patients formally consent 
with the procedures and were informed about the possible 
complications after the procedure like edema and intense 
pain. For all cases, analgesics were prescribed. Clinical and 
histopathological pictures describing the effectiveness of 
sclerotherapy are shown in Figures 1-3.  
DISCUSSION
Vascular low flow lesions may present progressive increase 
with age, trauma and after partial surgical resection. Ectasic 
blood vessels and reddish-blue surface are characteristically 
found in these lesions (2). Solitary presentation or multiple 
patterns may occur being non-isolated lesions possibly 
associated with syndromes like Maffuci, Sturge-Weber, 
Beckwith-Wiedemann, Ascher and Cobb (1,12). Change 
on pressure is a common finding with return to the original 
color on withdrawal of pressure (13). We believe that our 
cases correspond to vascular low-flow malformations due 
to their reddish-purple aspect, consistence, response to 
diascopy and absence of vascular pulsation (2). 
 Oral vascular lesions are of  clinical importance to the 
dentist because they pose serious bleeding risk induced 
during normal procedures like orthodontics or oral surgery 
resulting in need of clinical treatment (14). Management of 
vascular lesions includes the injection of sclerosant subs-
tances, which is a safe and effective primary treatment (13). 
A study with Sudanese patients with esophageal varices 
demonstrated that MO was useful to reduce the bleeding 
Fig. 2. Case four. Clinical features of a vascular low flow lesion before MO (A). Complete resolution after 
MO sclerotherapy (B). 
Fig. 3.  Histopathological features showing connective tissue with wide bundles of colagenous fibers with non-organized distri-
bution, small blood vessels and sparse mononuclear infiltrate (HE, X400) (A).  Microscopically, a large thrombus inside a blood 
vessel without recognized endothelial cells (B) (HE, X100). 
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consequent to portal hypertension (9). In one analysis done 
with 25 patients with craniofacial venous malformations, 
MO at 5% was applied inside the lesions and was effective 
for 14 of 16 patients who underwent sclerotherapy as the 
only treatment (11). Other report cited varicosities in the 
buccal mucosa treated with monoethanolamine oleate with 
resolution after three sessions (10). Even when the sclerothe-
rapy with MO reduced the lesion only partially, it provided 
good preparation for further surgery of residual lesion (8). 
In our cases, the larger lesions were reduced and in one case, 
it could be removed surgically. In other case, preservation 
was indicated due to a diffuse residual lesion.  In another 
study, 9 cases of pyogenic granuloma were treated by local 
injection of MO solution with excellent results. Scars were 
inconspicuous in all cases and complications occurred in 
only one patient who complained of pain due to an avoida-
ble injection of excess solution. (7). In our cases, only slight 
edema and mild pain after the injections were referred in 
two cases. Other clinical trial confirmed the efficacy of MO 
application in lip hemangioma with complete resolution 
(13). The injection of MO should be slow and careful and 
the doses per application have been less than 2 mL with the 
minimum interval of 7 days between them (13). The usual 
concentration choice is 5 % been necessary to observe that 
reduced concentrations may be useful to control side effects 
like pain and inflammation (10, 13). In our cases we diluted 
to 2.5% in distilled water, and the patients did not complain 
about pain or discomfort after the injections and clinical 
result was satisfactory. 
The mechanism of action of MO involves tissue necrosis, 
direct damage over the venous endothelium, induction of 
thrombus formation and balanced action over hemostasis 
(13,15). However, there are no studies which deal with his-
tological alterations in oral vascular malformation caused 
by MO. In a study that analyzed the effect of MO at venous 
dog wall, it was observed that venous thrombosis with signs 
of organization. Reactive inflammatory process, sclerosant 
spillage and hyaline amorphous material deposition were 
shown in the adventitia layer (15). These data are according 
with our findings, corroborating the thrombosis induction 
inside the vessels, mild inflammatory infiltrate and hyalini-
zation of adjacent connective tissue.    
CONCLUSION
In summary, we presented six cases of low flow vascular 
lesions treated with 2.5% monoethanolamine oleate with 
good results, showing the histological confirmation of its 
efficacy and practically lack of  severe clinical complications 
and complaints.   
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